Chemoprevention of lung cancer

Lancet Oncology

Volumn 4, Issue 11, 2003, Pages 659-669

  Soria, Jean Charles ^a   Kim, Edward S ^b   Fayette, Jérôme ^a   Lantuejoul, Sylvie ^c   Deutsch, Eric ^a   Hong, Waun Ki ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TEXAS   (United States)

^c Lung Cancer Research Group   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BETA CAROTENE; CALCIUM; CYANOCOBALAMIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ETRETINATE; FINASTERIDE; FOLIC ACID; GEFITINIB; GROWTH INHIBITOR; IBUPROFEN; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR BETA; RETINOID DERIVATIVE; RETINOL; RETINOL PALMITATE; SELENIUM; TAMOXIFEN; TELOMERASE; TIPIFARNIB; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; ENZYME ACTIVITY; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MALE; ONCOGENE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING CESSATION; TUMOR SUPPRESSOR GENE;

EID: 0242523007     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01244-0     Document Type: Review

References (81)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-56.
2. Jemal A, Thomas A, Murray T, et al. Cancer statistics. CA Cancer J Clin 2002; 52: 23-47.
3. Bray F, Sankila R, Ferlay J, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
4. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278: 1073-77.
5. Mao LM, El-Naggar A, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant lesions after chemopreventive therapy. J Natl Cancer Inst 1998; 90: 1545-51.
6. Bartsch H, Petruzzelli S, De Flora S, et al. Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 1992; 98: 119-24.
7. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratifies squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: 963-68.
8. Toloza EM, Roth JA, Swisher SG. Molecular events in bronchogenic carcinoma and their implications for therapy. Semin Surg Oncol 2000; 18: 91-99.
9. Drakoulis N, Cascorbi I, Brockmoller J, et al. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Invest 1994; 72: 240-48.
10. Heckbert SR, Weiss NS, Hornung SK, et al. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 1992; 84: 414-22.
11. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000; 92: 1764-72.
12. Sozzi G, Miozzo M, Tagliabue E, et al. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res 1991; 51: 400-04.
13. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997; 89: 857-62.
14. Thiberville L, Payne P, Vielkinds J, et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 1995; 55: 5133-39.
15. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89: 1366-73.
16. Rossell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993; 8: 2407-12.
17. Gosney JR, Field JK, Gosney MA, et al. c-myc oncoprotein in bronchial carcinoma: expression in all major morphological types. Anticancer Res 1990; 10: 623-28.
18. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68: 162-65.
19. Fukuse T, Hirata T, Naiki H, et al. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000; 60: 242-44.
20. Soria JC, Jang SJ, Khuri F, et al. Overexpression of cyclin B1 in early stage non-small cell lung cancer and its clinical implication. Cancer Res 2000; 60: 400-04.
21. INK4, Cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 1999; 5: 243-50.
22. Shriver SP, Bourdeau HA, Gubish CT, et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst 2000; 92: 24-33.
23. Lane D. P53, guardian of the genome. Nature 1992; 358: 15-16.
24. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
25. Takahashi T, Takahashi T, Suzuki H, et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991; 6: 1775-78.
26. Kishimoto Y, Murakami Y, Shiraishi M, et al. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 1992; 52: 4799-804.
27. Brambilla E, Gazzeri S, Lantuejoul S, et al. P53 mutant phenotype and deregulation of P53 transcription pathway (Bcl2, Bax, Wafl) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998; 4: 1609-18.
28. Reissmann PT, Koga H, Takahashi R, et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 1993; 8: 1913-19.
29. Gazzeri S, Gouyer V, Vour'ch C, et al. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 1998; 16: 497-504.
30. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of P16INK4 is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95: 11891-96.
31. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchioloalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91: 332-39.
32. Mao L. Tumor suppressor genes: does FHIT fit? J Natl Cancer Inst 1998; 90: 412-14.
33. Roz L, Gramegna M, Ishii H, et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002; 99: 3615-20.
34. Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997; 57: 2121-23.
35. 2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-94.
36. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-64.
37. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7: 861-67.
38. Subbaramiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase 2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56: 4424-29.
39. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816-20.
40. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis. J Natl Cancer Inst 1998; 90: 1609-20.
41. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001.
42. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5: 1001-05.
43. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-94.
44. Hida T, Kozaki K, Muramatsu H, et al Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6: 2006-11.
45. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995; 87: 895-902.
46. Soria JC, Xu X, Liu DD, et al. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst 2003; 95: 165-68.
47. Albanell J, Lonardo F, Rusch V, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic state. J Natl Cancer Inst 1997; 89: 1609-15.
48. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor β in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 1995; 332: 1405-10.
49. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35: 1332-38.
50. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994; 12: 851-73.
51. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501-05.
52. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
53. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92: 977-86.
54. Heimburger DC, Alexander CB, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA 1988; 259: 1525-30.
55. Lee JS, Lippman SM, Benner SE, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12: 937-45.
56. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 11: 1216-22.
57. The Alpha-tocopherol, beta-carotene cancer prevention study group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
58. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-55.
59. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-49.
60. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000; 6: 2973-79.
61. Wang XD, Liu C, Bronson RT, et al. Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 1999; 91: 60-66.
62. Paolini M, Cantelli-Forti G, Perocco P, et al. Co-carcinogenic effect of beta-carotene. Nature 1999; 398: 760-61.
63. Auerbach O, Gere JB, Forman JB, et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N Engl J Med 1957; 256: 98-104.
64. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs 1970-1977. N Engl J Med 1979; 300: 381-86.
65. Auerbach O, Stout AP, Hammond EC, et al. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961; 265: 253-67.
66. Gouveia J, Hercend T, Lemaigre G, et al. Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet 1982; 1: 710-12.
67. Mathe G, Gouveia J, Hercend R, et al. Correlation between precancerous bronchial metaplasia and cigarette consumption, and preliminary results of retinoid treatment. Cancer Detect Prev 1982; 5: 461-66.
68. Heimberger DC, Alexander CB, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12: report of a preliminary randomized double-blind intervention trial. JAMA 1988; 259: 1525-30.
69. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328: 15-20.
70. Lam S, MacAulay C, Le Riche JC, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002; 94: 1001-09.
71. Kurie JM, Lotan R, Lee JJ, et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003; 95: 206-14.
72. Decker J, Goldstein JC. Risk factors in head and neck cancer. N Engl J Med 1982; 306: 1151-55.
73. Boice JD, Fraumeni JF. Second cancer following cancer of the respiratory system in Connecticut, 1935-1982. Natl Cancer Inst Monogr 1985; 68: 83-98.
74. De Vries N, Snow GB. Multiple primary tumours in laryngeal cancer. J Laryngol Otol 1986; 100: 915-918.
75. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184-93.
76. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung. J Natl Cancer Inst 2001; 93: 605-18.
77. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002; 9: 693-95.
78. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-94.
79. Arnold AM, Browman GP, Levine MN, et al. The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 1992; 65: 737-43.
80. van Poppel G, Kok FJ, Hermus RJ. Beta-carotene supplementation in smokers reduces the frequency of micronuclei in sputum. Br J Cancer 1992; 66: 1164-68.
81. McLarty JW, Holiday DB, Girard WM, et al. Beta-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 1995; 62: 1431S-38S.